Innovent Biologics Overview
Latest PEG ratio for Innovent Biologics: 231.51 — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow231.51
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for IVBXF is 231.51. That is above the Healthcare sector average of 11.77. Investors often review this figure alongside Innovent Biologics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, IVBXF currently prints 231.51 for PEG ratio, while the sector average sits near 11.77. That is roughly 1866.6% above the sector mean. Large gaps often invite a closer look at Innovent Biologics's growth, margins, and balance sheet.
A PEG ratio of 231.51 for Innovent Biologics is not 'good' or 'bad' on its own. Compare it with the peer average (11.77) and with IVBXF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting IVBXF's PEG ratio (231.51), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Innovent Biologics's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
